Light source is critical to induce glioblastoma cell death by photodynamic therapy using chloro-aluminiumphtalocyanine albumin-based nanoparticles

Autor(es)

Davanzo, Nathalia Nossi ^[1] ; Pellosi, Diogo Silva ^[1] ; Franchi, Leonardo Pereira ^[1] ; Tedesco, Antonio Claudio ^[1]

Afiliação do(s) autor(es)

^[1] Univ Sao Paulo, Ctr Nanotechnol & Tissue Engn, Fac Philosophy Sci & Letters Ribeirao Preto, Photobiol & Photomed Res Grp, Dept Chem, Av Bandeirantes 3900, 14040-901 Vila Monte Alegre, Sao Paulo - Brazil

• Tipo de documento: Artigo Científico
• Fonte: Photodiagnosis and Photodynamic Therapy; v. 19, p. 181-183, SEP 2017.
• Citações Web of Science: 7

Resumo

Selection of an efficient light source is fundamental in the development of photodynamic therapy (PDT) protocols. However, few studies provide a comparison of different light sources with regard to phototoxic effects. Here, we compared the cell death induced by photoactivation of chloro-aluminiumphtalocyanine (AlClPc)-loaded human serum albumin nanoparticles under irradiation with different light sources: continuous laser (CL), pulsed laser (PL), and light -emitting diode (LED). Cells were exposed to three different AIC1Pc concentrations (1, 3, and 5 mu M) and three different light doses (200, 500, and 700 mJ/cm(2)) for each light source. Cell death and differentiation of apoptosis and necrosis pathway were measured by flow cytometry. CL was the best light source for improving the photodynamic action of AlClPc-loaded albumin nanoparticles in glioblastoma cells and avoiding undesirable side effects, especially at low photosensitizer doses (200 mJ/cm(2)). In addition, apoptosis was the main cell death pathway in all evaluated cases (70% for CL, and greater than 50% for PL and LED). In conclusion, the search for optimal light sources and light/photosensitizer doses is a crucial step in improving PDT outcomes and enhancing the clinical translation of PDT. (AU)

• Processo FAPESP: 16/00389-3 - Nanopartículas multifuncionais para a entrega sítio-específica da temozolomida® e verteporfina® para a terapia combinada de tumores cerebrais
• Beneficiário: Diogo Silva Pellosi
• Modalidade de apoio: Bolsas no Brasil - Pós-Doutorado
• Processo FAPESP: 13/50181-1 - Utilização de nanocarreadores contendo fármacos fotossensibilizantes e outros ativos aplicados à terapia celular e tratamento de patologias do sistema nervoso central
• Beneficiário: Antonio Claudio Tedesco
• Modalidade de apoio: Auxílio à Pesquisa - Temático
• Processo FAPESP: 14/11870-9 - Sensibilização de linhagens de câncer à terapia fotodinâmica por meio da inibição da proteína APE1
• Beneficiário: Leonardo Pereira Franchi
• Modalidade de apoio: Bolsas no Brasil - Pós-Doutorado